search
Back to results

A Safety and Efficacy Study of the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease

Primary Purpose

Humerus Pathological Fracture

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Photodynamic Bone Stabilization System
Sponsored by
IlluminOss Medical, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Humerus Pathological Fracture

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

-General Inclusion Criteria

  1. Skeletally mature adult males and females 18 years of age or older.
  2. Impending or actual pathological fracture of the humerus, secondary to metastatic bone disease.
  3. Females: neither pregnant nor intending to become pregnant during the course of the study, defined as:

    1. Postmenopausal for at least 1 year OR
    2. Documented oophorectomy or hysterectomy
    3. Surgically sterile OR
    4. If of childbearing potential, must be practicing double-barrier method of birth control, be willing to avoid pregnancy for the period of study participation and have a negative pregnancy test at screening
  4. Able to understand and provide informed consent.
  5. Willing and able to comply with post-operative treatment protocol and follow-up visit schedule.

    -Impending Fracture-Specific Inclusion Criteria

  6. Documented presence of solitary metastatic lesion.
  7. Mirels Criteria Score ≥ 8.
  8. Destruction of cortical bone at impending fracture site > 50%.

    -Actual Fracture-Specific Inclusion Criteria

  9. Radiograph-confirmed diagnosis of acute, single isolated fracture of the humerus. AO classification 11A1, 11A2 and 11B1, 11B2 and 12A1,12A2 and 12B1, 12B2 and 13A1,13A2 and 13B1, 13B2.
  10. Fracture is closed, Gustilo Type I or IIA.

Exclusion Criteria:

-General Exclusion Criteria

  1. Primary tumor (osteogenic origin, etc.) at site.
  2. Impending fracture or actual fracture location other than humerus.
  3. Current concomitant traumatic fracture of any other location.
  4. Active or incompletely treated infections that could involve the device implant site.
  5. Distant foci of infection that may spread to the implant site.
  6. Allergy to implant materials or dental glue.
  7. Vascular insufficiency, muscular atrophy, or neuromuscular disease at implant site.
  8. Uncooperative patients, or patients who are incapable of following directions (for example, as a consequence of a neurological or psychiatric disorder).

    -Impending Fracture-Specific Exclusion Criteria

  9. Mirels Score < 8.
  10. Destruction of cortical bone at impending fracture site < 50%.
  11. Prior surgery and/or prior fracture of affected site.
  12. Any articular component to impending fracture site.

    -Actual Fracture-Specific Exclusion Criteria

  13. Index treatment is greater than 28 days post fracture.
  14. Open fractures with severe contamination.
  15. Extremely comminuted fractures where insufficient holding power of the balloon on the intramedullary canal is probable.
  16. Delivery sheath is unable to cross fracture site after proper fracture reduction and realignment
  17. Patients whose intramedullary canal at site of fracture measures smaller than the diameter of the sheath provided.

Sites / Locations

  • Medical University of Vienna
  • St. Vinzenz-Hospital GmbH
  • Johannes Wesling Klinikum Minden
  • Lahn-Dill Kliniken
  • Medisch Spectrum Twente
  • Medical Center Leeuwarden

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Photodynamic Bone Stabilization System (PBSS)

Arm Description

The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.

Outcomes

Primary Outcome Measures

Pain Reduction
VAS Pain Score change of > -33% compared to baseline
Functional Improvement (Barthel Index of Activities of Daily Living (ADLs) improvement of > +10% from baseline -EORTC QLQ-C30 improvement of > +10% from baseline -EORTC QLQ-BM22 improvement of > +10% from baseline)
Barthel Index of Activities of Daily Living (ADLs) improvement of > +10% from baseline EORTC QLQ-C30 improvement of > +10% from baseline EORTC QLQ-BM22 improvement of > +10% from baseline
Clinical Safety Success (No Serious Device Related Complications -No additional surgical interventions: revisions, supplements, fixations or removals)
No Serious Device Related Complications No additional surgical interventions: revisions, supplements, fixations or removals
Radiographic Safety Success (No device fracture, migrations, mal-alignment or loss of reduction or fixation)
No device fracture, migrations, mal-alignment or loss of reduction or fixation

Secondary Outcome Measures

Pain Reduction (VAS Pain Score change of > -33% compared to baseline)
VAS Pain Score change of > -33% compared to baseline
Functional Improvement (-Barthel Index of Activities of Daily Living (ADLs) improvement of > +10% from baseline, -EORTC QLQ-C30 improvement of > +10% from baseline -EORTC QLQ-BM22 improvement of > +10% from baseline)
Barthel Index of Activities of Daily Living (ADLs) improvement of > +10% from baseline, EORTC QLQ-C30 improvement of > +10% from baseline EORTC QLQ-BM22 improvement of > +10% from baseline
Clinical Safety Success (No Serious Device Related Complications -No additional surgical interventions: revisions, supplements, fixations or removals)
No Serious Device Related Complications No additional surgical interventions: revisions, supplements, fixations or removals
Radiographic Safety Success (No device fracture, migrations, mal-alignment or loss of reduction or fixation)
No device fracture, migrations, mal-alignment or loss of reduction or fixation
Duration of index procedure and length of hospital stay
Disability status
Determined per Investigator assessment
Evaluation of duration of physical therapy prescription
Assessment of prescription and over-the-counter analgesic medication use
Survivability from time of index procedure to death
Incidence and number of AEs
Incidence and number of procedure- and device-related complications
Activities of Daily Living score through all follow-up intervals
Barthel Index of Activities of Daily Living (ADLs), EORTC QLQ-C30 and EORTC QLQ-BM22
VAS Pain score from baseline through all follow-up intervals
VAS pain scale

Full Information

First Posted
February 17, 2015
Last Updated
July 31, 2017
Sponsor
IlluminOss Medical, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02373904
Brief Title
A Safety and Efficacy Study of the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease
Official Title
A Prospective, Multi-Center Study of the IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease
Study Type
Interventional

2. Study Status

Record Verification Date
July 2017
Overall Recruitment Status
Completed
Study Start Date
February 2015 (undefined)
Primary Completion Date
December 2016 (Actual)
Study Completion Date
June 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
IlluminOss Medical, Inc.

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to collect safety and performance data of the Photodynamic Bone Stabilization System (PBSS) when used for the treatment of painful impending and actual fractures of the humerus secondary to metastatic cancer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Humerus Pathological Fracture

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
14 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Photodynamic Bone Stabilization System (PBSS)
Arm Type
Experimental
Arm Description
The PBSS is comprised of an inflatable, thin walled polyethylene terephthalate (PET; Dacron™) balloon mounted on an insertion catheter. This balloon catheter system is designed to deliver the monomer cement to the fracture site via the medullary canal of the bone.
Intervention Type
Device
Intervention Name(s)
Photodynamic Bone Stabilization System
Intervention Description
Treatment of impending and actual pathological fractures of the humerus
Primary Outcome Measure Information:
Title
Pain Reduction
Description
VAS Pain Score change of > -33% compared to baseline
Time Frame
90 days
Title
Functional Improvement (Barthel Index of Activities of Daily Living (ADLs) improvement of > +10% from baseline -EORTC QLQ-C30 improvement of > +10% from baseline -EORTC QLQ-BM22 improvement of > +10% from baseline)
Description
Barthel Index of Activities of Daily Living (ADLs) improvement of > +10% from baseline EORTC QLQ-C30 improvement of > +10% from baseline EORTC QLQ-BM22 improvement of > +10% from baseline
Time Frame
90 days
Title
Clinical Safety Success (No Serious Device Related Complications -No additional surgical interventions: revisions, supplements, fixations or removals)
Description
No Serious Device Related Complications No additional surgical interventions: revisions, supplements, fixations or removals
Time Frame
90 days
Title
Radiographic Safety Success (No device fracture, migrations, mal-alignment or loss of reduction or fixation)
Description
No device fracture, migrations, mal-alignment or loss of reduction or fixation
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Pain Reduction (VAS Pain Score change of > -33% compared to baseline)
Description
VAS Pain Score change of > -33% compared to baseline
Time Frame
90, 180 and 360 days
Title
Functional Improvement (-Barthel Index of Activities of Daily Living (ADLs) improvement of > +10% from baseline, -EORTC QLQ-C30 improvement of > +10% from baseline -EORTC QLQ-BM22 improvement of > +10% from baseline)
Description
Barthel Index of Activities of Daily Living (ADLs) improvement of > +10% from baseline, EORTC QLQ-C30 improvement of > +10% from baseline EORTC QLQ-BM22 improvement of > +10% from baseline
Time Frame
90, 180, 360 days
Title
Clinical Safety Success (No Serious Device Related Complications -No additional surgical interventions: revisions, supplements, fixations or removals)
Description
No Serious Device Related Complications No additional surgical interventions: revisions, supplements, fixations or removals
Time Frame
90, 180, 360 days
Title
Radiographic Safety Success (No device fracture, migrations, mal-alignment or loss of reduction or fixation)
Description
No device fracture, migrations, mal-alignment or loss of reduction or fixation
Time Frame
90, 180, 360 days
Title
Duration of index procedure and length of hospital stay
Time Frame
90, 180, 360 days
Title
Disability status
Description
Determined per Investigator assessment
Time Frame
90, 180, 360 days
Title
Evaluation of duration of physical therapy prescription
Time Frame
90, 180, 360 days
Title
Assessment of prescription and over-the-counter analgesic medication use
Time Frame
90, 180, 360 days
Title
Survivability from time of index procedure to death
Time Frame
90, 180, 360 days
Title
Incidence and number of AEs
Time Frame
90, 180, 360 days
Title
Incidence and number of procedure- and device-related complications
Time Frame
90, 180, 360 days
Title
Activities of Daily Living score through all follow-up intervals
Description
Barthel Index of Activities of Daily Living (ADLs), EORTC QLQ-C30 and EORTC QLQ-BM22
Time Frame
90, 180, 360 days
Title
VAS Pain score from baseline through all follow-up intervals
Description
VAS pain scale
Time Frame
90, 180, 360 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: -General Inclusion Criteria Skeletally mature adult males and females 18 years of age or older. Impending or actual pathological fracture of the humerus, secondary to metastatic bone disease. Females: neither pregnant nor intending to become pregnant during the course of the study, defined as: Postmenopausal for at least 1 year OR Documented oophorectomy or hysterectomy Surgically sterile OR If of childbearing potential, must be practicing double-barrier method of birth control, be willing to avoid pregnancy for the period of study participation and have a negative pregnancy test at screening Able to understand and provide informed consent. Willing and able to comply with post-operative treatment protocol and follow-up visit schedule. -Impending Fracture-Specific Inclusion Criteria Documented presence of solitary metastatic lesion. Mirels Criteria Score ≥ 8. Destruction of cortical bone at impending fracture site > 50%. -Actual Fracture-Specific Inclusion Criteria Radiograph-confirmed diagnosis of acute, single isolated fracture of the humerus. AO classification 11A1, 11A2 and 11B1, 11B2 and 12A1,12A2 and 12B1, 12B2 and 13A1,13A2 and 13B1, 13B2. Fracture is closed, Gustilo Type I or IIA. Exclusion Criteria: -General Exclusion Criteria Primary tumor (osteogenic origin, etc.) at site. Impending fracture or actual fracture location other than humerus. Current concomitant traumatic fracture of any other location. Active or incompletely treated infections that could involve the device implant site. Distant foci of infection that may spread to the implant site. Allergy to implant materials or dental glue. Vascular insufficiency, muscular atrophy, or neuromuscular disease at implant site. Uncooperative patients, or patients who are incapable of following directions (for example, as a consequence of a neurological or psychiatric disorder). -Impending Fracture-Specific Exclusion Criteria Mirels Score < 8. Destruction of cortical bone at impending fracture site < 50%. Prior surgery and/or prior fracture of affected site. Any articular component to impending fracture site. -Actual Fracture-Specific Exclusion Criteria Index treatment is greater than 28 days post fracture. Open fractures with severe contamination. Extremely comminuted fractures where insufficient holding power of the balloon on the intramedullary canal is probable. Delivery sheath is unable to cross fracture site after proper fracture reduction and realignment Patients whose intramedullary canal at site of fracture measures smaller than the diameter of the sheath provided.
Facility Information:
Facility Name
Medical University of Vienna
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Facility Name
St. Vinzenz-Hospital GmbH
City
Koln
ZIP/Postal Code
D-50733
Country
Germany
Facility Name
Johannes Wesling Klinikum Minden
City
Minden
ZIP/Postal Code
32429
Country
Germany
Facility Name
Lahn-Dill Kliniken
City
Wetzlar
ZIP/Postal Code
35578
Country
Germany
Facility Name
Medisch Spectrum Twente
City
Enschede
ZIP/Postal Code
7513 ER
Country
Netherlands
Facility Name
Medical Center Leeuwarden
City
Leeuwarden
ZIP/Postal Code
8934 AD
Country
Netherlands

12. IPD Sharing Statement

Learn more about this trial

A Safety and Efficacy Study of the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease

We'll reach out to this number within 24 hrs